Clinical Trial: To Explore the Efficacy of Sintilimab Combined with Bevacizumab in Rectal Cancer

U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT06808412) titled 'To Explore the Efficacy of Sintilimab Combined with Bevacizumab in Rectal Cancer' on Jan. 20.

Brief Summary: This is a prospective, exploratory clinical study. The primary endpoint of the study is to assess the pathological complete response (pCR) rate of tumors after neoadjuvant chemotherapy for rectal cancer using sintilimab combined with bevacizumab. The aim is to evaluate the efficacy and safety of sintilimab in combination with bevacizumab in the perioperative neoadjuvant chemotherapy for rectal cancer. The study includes two cohorts: Cohort A involves a retrospective collection of rectal cancer patients who previously received ...